Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2021. The registrant is a foreign private issuer based in Jerusalem, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a corporate transaction rather than a financial results statement.
Material Changes
The primary material event disclosed is the Company's contemplated underwritten public offering of 2,434,783 American Depositary Shares (ADS), with each ADS representing forty ordinary shares. An Underwriting Agreement was executed on January 29, 2021, with Aegis Capital Corp.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, or specific risk factors beyond the standard incorporation of exhibits related to the public offering. No unusual items or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the final terms and pricing of the 2,434,783 ADS offering.
- Confirm the execution of the Underwriting Agreement with Aegis Capital Corp. dated January 29, 2021.
- Review the legal opinion provided by Gross Law Firm (Exhibit 5.1) regarding the offering.
- Check subsequent filings for the actual proceeds raised and use of funds from this offering.